TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -15.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 7 | 0 | 3.13M | $2.08B | n/a | n/a |
| Q2 2026 | 191 | +3 | 260.72M | $131.51B | +5 | −1 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | n/a |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | n/a |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | n/a | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | n/a |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | n/a | −2 |
| Q2 2024 | 23 | n/a | 44.78M | $24.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Parnassus Investments, Llc | 1.46M | -10.8% | $987.79M | 2.9% | ▼ Trim | 4 | SEC ↗ |
| 2 | Robeco Institutional Asset… | 716.89K | +24.1% | $483.94M | 0.6% | ▲ Add | 4 | SEC ↗ |
| 3 | Ninety One UK Ltd | 528.09K | -11.1% | $356.49M | 0.8% | ▼ Trim | 4 | SEC ↗ |
| 4 | Assenagon Asset Management S.A. | 214.24K | -68.7% | $144.62M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 5 | Assetmark, Inc | 70.51K | +6.0% | $47.60M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | Wealth Enhancement Advisory… | 100.33K | +7.1% | $38.79M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | TD Waterhouse Canada Inc. | 32.98K | -21.3% | $21.54M | 0.1% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 24.30K shares, $11,944 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.73K sh · $2.29M
Officer · 400 sh · $245,752
Officer, Director · 62 sh · $38,982
Officer, Director · 33 sh · $20,677
Officer, Director · 101 sh · $63,166
Officer, Director · 79 sh · $49,613
Officer, Director · 2.15K sh · $1.35M
Officer, Director · 1.79K sh · $1.12M
Officer, Director · 3.01K sh · $1.89M
Officer, Director · 2.73K sh · $1.71M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology